A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer (NCT07337031) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
China193 participantsStarted 2026-01
Plain-language summary
Research purpose
1. To evaluate the impact of complex behavioral intervention on the one-year overall survival rate of patients with unresectable liver cancer after comprehensive treatment, a comparative study was conducted between the complex behavioral intervention group and the standard medical care control group, and the dose-response relationship between the intervention intensity and clinical outcomes was explored.
2. Analyze the impact mechanisms of complex behavioral interventions on patients' quality of life, adverse treatment reactions, and key biological indicators, including evaluating clinical outcomes such as 2-year overall survival rate, progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as the association between changes in related biomarkers and behavioral compliance.
3. Evaluate the implementation effect and sustainability of the "in-hospital face-to-face + wechat platform" hybrid intervention model, including intervention acceptance, long-term behavior maintenance, health economic benefits, and perioperative recovery of patients undergoing down-conversion surgery.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Pathologically or radiologically confirmed primary hepatocellular carcinoma;
✓. BCLC stage B-C, initially assessed as unresectable;
✓. Age 18-75 years;
✓. ECOG performance status score 0-2;
✓. Child-Pugh classification grade A or B (\<=9 points);
✓. Normal cognitive ability, capable of understanding and following intervention protocols;
✓. Both the patient and primary caregiver can use a smartphone and the WeChat platform and are able to complete questionnaires and follow-up tasks;
✓. Voluntarily participates in the study and signs the informed consent form.
Exclusion criteria
✕. Presence of malignant tumors in other organs;
✕. Presence of extrahepatic metastasis;
What they're measuring
1
Overall survival rate
Timeframe: The time from enrollment to death caused by any reason, mainly the one-year survival rate